Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 8.6% – Time to Buy?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded up 8.6% during mid-day trading on Friday . The stock traded as high as $7.00 and last traded at $6.93. 8,084,092 shares traded hands during mid-day trading, an increase of 35% from the average session volume of 6,003,390 shares. The stock had previously closed at $6.38.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on RXRX. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, November 20th. Jefferies Financial Group decreased their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Finally, Leerink Partners cut their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and an average price target of $9.25.

Recursion Pharmaceuticals Stock Up 10.8 %

The firm has a market capitalization of $2.03 billion, a PE ratio of -4.62 and a beta of 0.81. The stock has a 50-day simple moving average of $6.57 and a 200-day simple moving average of $7.40. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company’s revenue was up 147.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.43) earnings per share. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $6.27, for a total transaction of $71,772.69. Following the sale, the director now owns 7,121,322 shares in the company, valued at $44,650,688.94. This represents a 0.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Christopher Gibson sold 20,000 shares of Recursion Pharmaceuticals stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total value of $120,800.00. Following the completion of the transaction, the chief executive officer now owns 762,656 shares of the company’s stock, valued at approximately $4,606,442.24. This trade represents a 2.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 165,682 shares of company stock valued at $1,088,111. Company insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in Recursion Pharmaceuticals by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 16,014,764 shares of the company’s stock worth $159,667,000 after purchasing an additional 349,554 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Recursion Pharmaceuticals by 9.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 62,065 shares of the company’s stock worth $619,000 after buying an additional 5,501 shares in the last quarter. California State Teachers Retirement System boosted its stake in Recursion Pharmaceuticals by 3.2% during the first quarter. California State Teachers Retirement System now owns 154,491 shares of the company’s stock valued at $1,540,000 after buying an additional 4,828 shares during the period. Teachers Retirement System of The State of Kentucky grew its position in Recursion Pharmaceuticals by 9.7% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 187,927 shares of the company’s stock worth $1,873,000 after buying an additional 16,600 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in Recursion Pharmaceuticals by 1,588.4% in the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after acquiring an additional 6,036 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.